Biovitrum, Karolinska Development deal

Biovitrum and Karolinska formed an unnamed JV to develop and commercialize Biovitrum's low-molecular inhibitors of FMS-like tyrosine kinase 3 ( FLT3), which are in preclinical testing for leukemia. B...